Diagnostic Role of Aldoketoreductase family 1B10 (AKR1B10) in Hepatocellular Carcinoma and Benign Hepatic Lesions

Abstract

epatocellular carcinoma (HCC) is the most common primary liver cancer. It is the second most common cause of cancer deaths. Globally it is the fifth most common cancer accounting for 9.1 % of global cancer. In Egypt; according to Cancer Pathology Registry (Pathology Department, Ain Shams University) HCC accounted for (88.3%) of the primary liver tumors and (45.84%) based on the Cancer Pathology Registry (National Cancer Institute, Cairo University). The majority of HCCs arise in chronically diseased livers with or without cirrhosis. Hepatocarcinogenesis is a multistep process. Several benign lesions might be found in a cirrhotic background along with hepatocellular carcinoma (HCC), and may exhibit typical or atypical imaging features. However, histopathological distinction can be challenging, particularly when the diagnostic material is limited and when well differentiated HCC is considered despite the variety of tumor markers that have been studied in HCC this of crucial clinical importance in determining appropriate therapy and assessing the prognosis. The aim of our work is to study the immuno-histochemical expression of Aldoketoreductase family 1B10 (AKR1B10) in hepatocellular carcinoma and benign hepatic lesions, to assess its role in the diagnosis of hepatocellular carcinoma and in differentiating it from different benign hepatic lesions. This study included (217) cases.120 cases were received at the Pathology department Ain Shams (Al-Demerdash) Hospital and Ain-Shams University Specialized Hospital during the period (2009-2014) and 98 cases were received at